Everything was as expected when the US Federal Trade Commission finallygave the go-ahead to the two Swiss firms Ciba and Sandoz to merge into the new global number one life sciences entity, Novartis (Marketletter December 23, 1996).
The conditions laid down for the merger by the FTC were that the US corn herbicide busines be divested, along with flea and tick control products within the animal health business. Also, the FTC required that Novartis provide access to its gene therapy.
Ciba and Sandoz have already disposed of the corn herbicides business, which has been acquired by BASF for $778 million, and animal health products have been sold off for $42 million to Central Garden.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze